Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.969
Abstract: Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This… read more here.
Keywords: omecamtiv mecarbil; hepatic impairment; moderate hepatic; impairment ... See more keywords
Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca2+ levels
Sign Up to like & getrecommendations! Published in 2023 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14300
Abstract: Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments, that is, direct activators of the myosin molecule and Ca2+ sensitizers… read more here.
Keywords: omecamtiv mecarbil; cardiomyocyte contractile; mecarbil augments; augments cardiomyocyte ... See more keywords
Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-021-01052-3
Abstract: Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two modified-release (MR) novel OM minitablet formulations were developed to support the planned investigation of chronic heart failure… read more here.
Keywords: omecamtiv mecarbil; minitablet formulations; adult; bioavailability ... See more keywords
The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cardiac Failure"
DOI: 10.1016/j.cardfail.2020.09.017
Abstract: Background Omecamtiv mecarbil (OM) is a cardiac myotrope which selectively activates cardiac myosin and thereby increases cardiac contractility. The aim of the current study was to determine the effect of therapy with OM on right… read more here.
Keywords: omecamtiv mecarbil; right ventricular; cardiac myosin; failure ... See more keywords
EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)31299-9
Abstract: Atrial fibrillation/ flutter (AF) is a common comorbidity in patients with heart failure (HF). We examined the influence of AF on the response to the selective cardiac myosin activator, omecamtiv mecarbil (OM), in patients with… read more here.
Keywords: atrial fibrillation; omecamtiv mecarbil; mecarbil patients; heart failure ... See more keywords
Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
Sign Up to like & getrecommendations! Published in 2018 at "Nature Communications"
DOI: 10.1038/s41467-018-06193-2
Abstract: Omecamtiv mecarbil (OM) is a positive cardiac inotrope in phase-3 clinical trials for treatment of heart failure. Although initially described as a direct myosin activator, subsequent studies are at odds with this description and do… read more here.
Keywords: omecamtiv mecarbil; myosin; cardiac inotrope; working stroke ... See more keywords
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Sign Up to like & getrecommendations! Published in 2022 at "European heart journal"
DOI: 10.1093/eurheartj/ehac144
Abstract: AIMS In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction. We explored the influence… read more here.
Keywords: omecamtiv mecarbil; heart failure; effect; heart ... See more keywords
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
Sign Up to like & getrecommendations! Published in 2022 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehac293
Abstract: Abstract Aim Patients with heart failure with reduced ejection fraction and low systolic blood pressure (SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical treatment. Omecamtiv mecarbil may be particularly helpful in such patients.… read more here.
Keywords: omecamtiv mecarbil; heart failure; sbp 100; 100 mmhg ... See more keywords
Abstract 416: Sarcomere Disassembly After Unloading is Regulated by Ubiquitination and Acetylation of Capz and α-actinin
Sign Up to like & getrecommendations! Published in 2020 at "Circulation Research"
DOI: 10.1161/res.127.suppl_1.416
Abstract: Cardiac function mainly depends on the total myocyte mass in the ventricles. Assembly and disassembly of sarcomeres occurs to adjust this mass to altered mechanical demand. In the heart, hypertrophic cardiomyopathy results from myofibrillar assembly… read more here.
Keywords: disassembly unloading; omecamtiv mecarbil; acetylation; sarcomere disassembly ... See more keywords
Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-018-0831-3
Abstract: BackgroundAortic regurgitation (AR) is a valvular disease that can lead to systolic heart failure. Treatment options besides cardiac surgery are limited and consequently severe AR is associated with higher mortality and morbidity when not operated.… read more here.
Keywords: activator omecamtiv; omecamtiv mecarbil; myosin activator; cardiac myosin ... See more keywords
Detection of soluble suppression of tumorigenicity 2 and N-terminal B-type natriuretic peptide in a rat model of aortic regurgitation: differential responses to omecamtiv mecarbil
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Basic and Clinical Physiology and Pharmacology"
DOI: 10.1515/jbcpp-2022-0215
Abstract: Abstract Objectives Both N-terminal fragment of B-type natriuretic peptide (NT-proBNP) and soluble isoform of ST2 (sST2) have been identified as biomarkers of heart failure. We evaluated the plasma levels of NT-proBNP and sST2 in a… read more here.
Keywords: omecamtiv mecarbil; type natriuretic; natriuretic peptide; rat model ... See more keywords